The Neisseria meningitidis Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neisseria meningitidis Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued products.
GlobalData tracks 41 drugs in development for Neisseria meningitidis Infections by 28 companies/universities/institutes. The top development phase for Neisseria meningitidis Infections is preclinical with 13 drugs in that stage. The Neisseria meningitidis Infections pipeline has 35 drugs in development by companies and six by universities/ institutes. Some of the companies in the Neisseria meningitidis Infections pipeline products market are: GSK, Suzhou Weichao Biotechnology and Techinvention Lifecare.
The key targets in the Neisseria meningitidis Infections pipeline products market include Meningococcal Capsular Polysaccharide Antigen, Neisseria meningitidis Factor H Binding Lipoprotein, and Poly N-Acetyl Glucosamine.
The key mechanisms of action in the Neisseria meningitidis Infections pipeline product include Complement C1s Subcomponent Inhibitor with one drug in Preclinical. The Neisseria meningitidis Infections pipeline products include six routes of administration with the top ROA being Intramuscular and eight key molecule types in the Neisseria meningitidis Infections pipeline products market including Conjugate Vaccine, and Subunit Vaccine.
Neisseria meningitidis Infections overview
Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.
For a complete picture of Neisseria meningitidis Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
